Xenon Pharmaceuticals is a Canadian biopharma company targeting neurological diseases with a focus on ion channel-blocking technology. The clinical stage asset, azetukalner, is in late stage ...

Genep Inc. has divulged sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the treatment of epilepsy.

Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...

Sodium channel blockers are medications that help reduce abnormal electrical activity in the heart. They can also lower the risk of severe complications such as stroke or sudden cardiac death. Sodium ...

Genep Inc. has prepared and tested Imidazole compounds acting as sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the treatment of epilepsy.

Praxis Precision Medicines, Inc. uses a genetics-driven approach to develop potential best-in-class drugs for patients with central nervous system (CNS) disorders that are characterized by faulty ...

LOS ANGELES -- Use of angiotensin receptor blockers (ARBs) was linked to a lower risk of epilepsy after an acute ischemic stroke, according to an observational study. Among hypertensive patients, ARB ...